PMID- 15730935
OWN - NLM
STAT- MEDLINE
DCOM- 20050406
LR  - 20061115
IS  - 1499-3872 (Print)
VI  - 4
IP  - 1
DP  - 2005 Feb
TI  - Effects of dendritic cells transfected with full length wild-type p53 and 
      modified by bile duct cancer lysates on immune response.
PG  - 121-5
AB  - BACKGROUND: Dendritic cells (DCs) are the most potent antigen-presenting cells 
      and are actively used in cancer immunotherapy. Wild-type p53 can be recognized as 
      an antigen and can induce specific cytotoxic T lymphocytes (CTLs) in the host 
      body. The aim of this study was to investigate the effects of DCs transfected 
      with full length wild-type p53 and modified by bile duct lysates on immune 
      response. METHODS: The wild-type p53 was transducted to DCs with adenovirus, 
      which were modified by bile duct lysates (Lywtp53DC). The concentration of the 
      surface molecules (B7-1, B7-2, MHC-I, MHC-II) of all DCs was detected with 
      fluorescence activated cell sorter (FACS), and the ability of the DCs to induce 
      efficient and specific immunological response in anti-(51)Cr-labeled target cells 
      was studied. BALB/c mice infected with the DCs and QBC939 were used. CTL response 
      in mice immunized with Lywtp53DC and treatment of tumor-bearing mice with 
      Lywtp53DC and CTL response in these mice were studied. RESULTS: The surface 
      molecules of Lywtp53DC had a high expression B7-1 (86.70%+/-0.07%), B7-2 
      (18.77%+/-0.08%), MHC-I(87.20%+/-0.05%), MHC-II(56.70%+/-0.07%) with FACS. The T 
      lymphocytes had a specific CTL lysing ability induced by Lywtp53DC, with a CTL 
      lysis rate of 81%. The immune protection of Lywtp53DC group was obvious, and the 
      tumor diameter of the Lywtp53DC group was 3.10+/-0.31 mm, 2.73+/-0.23 mm, 
      3.70+/-0.07 mm on days 13, 16 and 19, smaller than those of any control groups 
      (P<0.05), DC, wtp53DC and LyDC. On the other hand, the growth rate of tumor of 
      the Lywtp53DC group was slower than that of any other groups (P<0.05). 
      CONCLUSION: Dendritic cells transfected with wild-type p53 and modified by bile 
      duct lysates have specific CTL killing capability.
FAU - Sun, Hua-Wen
AU  - Sun HW
AD  - Department of General Surgery, Renmin Hospital, Wuhan University, Wuhan 430060, 
      China. sxshwyq@sina.com
FAU - Tang, Qi-Bing
AU  - Tang QB
FAU - Tang, Chong
AU  - Tang C
FAU - Zou, Sheng-Quan
AU  - Zou SQ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Singapore
TA  - Hepatobiliary Pancreat Dis Int
JT  - Hepatobiliary & pancreatic diseases international : HBPD INT
JID - 101151457
RN  - 0 (Tissue Extracts)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Animals
MH  - Bile Duct Neoplasms/*immunology/*therapy
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/*immunology
MH  - Disease Models, Animal
MH  - Female
MH  - Genes, p53
MH  - *Immunotherapy, Adoptive
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Sensitivity and Specificity
MH  - Tissue Extracts/immunology
MH  - Transfection
MH  - Treatment Outcome
MH  - Tumor Suppressor Protein p53/*immunology
EDAT- 2005/02/26 09:00
MHDA- 2005/04/07 09:00
CRDT- 2005/02/26 09:00
PHST- 2005/02/26 09:00 [pubmed]
PHST- 2005/04/07 09:00 [medline]
PHST- 2005/02/26 09:00 [entrez]
AID - 366 [pii]
PST - ppublish
SO  - Hepatobiliary Pancreat Dis Int. 2005 Feb;4(1):121-5.